Bacil Pharma Ltd — Updates, 26-05-2025: Company Update

Bacil Pharma Limited has announced a board meeting to approve the financial results for the quarter and half-year ended March 31, 2025. The company reported total revenue of ₹66.14 lakh for the year, primarily from other income, with expenses totaling ₹25.39 lakh. It delivered a profit after tax of ₹40.41 lakh for the year, a significant improvement from a loss in the previous year. Earnings per share stood at ₹0.64. The company’s net worth rose sharply to ₹2543.13 lakh from ₹121.32 lakh, fueled by a preferential allotment raising ₹276 lakh. The statutory auditor issued an unmodified opinion but flagged uncertainty over recoverability of outstanding loans and advances. Cash and cash equivalents surged to ₹285.73 lakh, supported by robust operating cash flows and fresh equity infusion. This financial turnaround and strengthened balance sheet could interest investors monitoring Bacil Pharma’s recovery trajectory.